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1. Introduction
Ovarian  cancer  is  currently  the  fifth  most  lethal  malignancy  of  women  in  Europe  and
the United States  [1,  2].  The prognosis  of  ovarian cancer patients  is  limited due to lack
of specific early symptoms and a high rate of relapse; more than half of all patients will
suffer from disease recurrence, resulting in a poor overall survival [3]. Most cases are di‐
agnosed in advanced stages, and although the initial response to chemotherapy is gener‐
ally good, a significant proportion of patients will  suffer from a relapse despite optimal
cytoreductive surgery [4].  Since treatment strategies are mainly developed to control  lo‐
coregional  cancer  growth,  it  may  be  anticipated  that  more  women  will  die  of  distant
metastatic  disease.  The  identification  of  novel  molecular  markers,  reflecting  current  tu‐
mor activity,  may improve prediction and therapy monitoring and provide valuable in‐
sights into process of carcinogenesis. In this regard, oncologic research have increasingly
focused on disseminated and circulating tumor cells.
The presence of disseminated tumor cell (DTC) in bone marrow (BM) is a phenomenon ob‐
served in almost all solid tumors of epithelial origin. For breast cancer, DTC presence has
been demonstrated as a strong independent prognostic factor (level I evidence) [5]. Availa‐
ble data support the notion that hematogenous tumor cell dissemination may be clinically
relevant in ovarian cancer as well [6-10]. Detection rates of DTC, as a surrogate parameter
for occult hematogenous spread, vary between 30-50% primary ovarian cancer patients.
A provocative hypothesis has been introduced recently with respect to natural history and
progression of ovarian cancer. While the ‘classical’ stochastic model of cancer development
holds that any cell may become source of malignant transformation, emerging evidence sup‐
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ports the view that only a minor subpopulation of cancer cells has the potential to initiate
cancer growth. These cells, called cancer stem cells (CSC), have the ability to self-renew,
propagate tumorigenesis and are usually drug-resistant [11]. Experimental studies on stem
cell biology have given new impetus to the cancer stem cell theory. CSC are assumed to play
important role in development of various tumor entities, such as breast and gastrointestinal
cancer, retinoblastoma and ovarian cancer [12], [13]. Interestingly, ovarian cancer cell lines
feature “side population” cells with potential to differentiate into cancers with different his‐
tologies, suggesting the pluripotent character of stem cells [14]. Whether DTC in extraperito‐
neal sites, such as bone marrow, reflect a stem cell-like sub population of tumor cells,
remains yet to be cleared.
Of all prognostic factors, monitoring of minimal residual disease is the only one available
after the tumor has been removed. Beside monitoring of tumor markers, there is currently a
major effort to identify other biological markers which can be assessed with minimally inva‐
sive methods and persist beyond surgery. We previously reported on a significant correla‐
tion of positive BM status with shortened relapse-free survival in ovarian cancer patients [6].
DTC persistence after completion of platinum-based chemotherapy was also found to be
prognostically relevant [15]. Recently, attempts have been made to target DTC by using anti‐
body-based therapy with the trifunctional antibody catumaxomab. Wimberger et al. report‐
ed a marked decrease in tumor cells in peripheral blood following intraperitoneal
catumaxomab treatment for malignant ascites, indicating a systemic effect of the therapy
[16]. However, in comparison with breast cancer, data on DTC detection in gynecological
malignancies are so far limited [7], [17], [18], [19], [9].
In this chapter we discuss recent advances in ovarian cancer research with respect to disse‐
minated tumor cells and cancer stem cell hypothesis. Data on prognostic and clinical rele‐
vance are presented.
2. Disseminated and circulating tumor cells in ovarian cancer
Detection and characterization of disseminated tumor cells in bone marrow and blood of pa‐
tients with epithelial carcinomas can be accomplished by various techniques. For the detec‐
tion of isolated tumor cells, both antibody-based assays and molecular assays have been
established [20, 21]. Despite advances in this field, no specific antigen or marker gene has
been described for ovarian cancer so far. Therefore, immunocytochemical identification of
these cells based on expression of epithelial markers remains the gold standard (Figure 1).
Commonly targeted antigens are cytokeratin and EpCAM due to relatively constant and
universal expression pattern in cells of epithelial origin [9, 15, 22]. A major difficulty in de‐
tecting and characterizing tumor cells is their relatively low frequency. Most protocols in‐
clude therefore a cell enrichment step (e.g. density gradient centrifugation,
immunomagnetic enrichment). These obstacles highlight the need for optimization of the as‐
say (e.g. by minimizing cell loss, preserving cell morphology and producing reliable immu‐
nophenotypic and genotypic data) as it is essential for detecting, enumerating and
characterizing single tumor cells [21].
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Figure 1. Disseminated tumor cell from ovarian cancer patient with typical cytomorphology and immunophenotype
(positive cytokeratin-staining, large nucleus, high nuclear to cytoplasmic ratio, nucleus partially covered by CK-stain‐
ing, nucleus granular [23].
Detection rates of disseminated tumor cells in ovarian cancer patients stage FIGO I-III reach
20-60% [7, 9, 15, 22]. These results suggest hematogenous spread to be a comparatively fre‐
quent phenomenon in ovarian malignancies and indicate the ability of single tumor cells to
disseminate to bone marrow in a very early stage of disease. DTC are routinely detected in
13-18% FIGO I ovarian cancer patients [6, 19, 22]. Since bone metastases are relatively rare in
ovarian cancer patients, BM seems to serve as a temporary `homing site´ for single tumor
cells, from where they are able to migrate and subsequently cause distant metastasis or local
recurrence [24]. Assuming that DTC may spread by means of blood stream we cannot ex‐
clude that those may also be able to repopulate the peritoneal cavity, an environment which
easily supports ovarian cancer growth [11, 25].
Based on numerous studies,  no significant relationship has been reported between clini‐
copathological  characteristics  of  primary  tumor  and  DTC  detection.  In  our  latest  trial
with  414  ovarian cancer  patients,  DTC status  did not  correlate  with  FIGO stage,  tumor
size, lymph node status, histopathologic grading or resection status [26, 27]. Braun et al.,
in  a  cohort  of  108  primary  ovarian  cancer  patients,  showed  no  concordance  between
classical  prognostic  factors  and DTC positivity.  The only factor  associated with positive
DTC status  was tumor grading (p  =  0.02)  [7].  These  results  could be  also  confirmed in
our earlier study with 112 ovarian cancer patients [6]. Similar findings were obtained by
other investigators [8, 9, 15, 19].
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2.1. Prognostic relevance of DTC/CTC in ovarian cancer
Detection  of  disseminated  tumor  cells  in  patients  with  primary  ovarian  cancer  was
shown  to  be  of  prognostic  value  (Table  1).  However,  the  currently  available  data  are
sparse.  In  our latest  trial  bone marrow status of  414 ovarian cancer  patients  was corre‐
lated  with  clinical  follow-up  [26].  The  presence  of  DTC  predicted  a  shorter  OS  (p  <
0.001)  and  DFS  (p  =  0.035)  compared  with  BM  negative  patients  [27];  this  association
was highly significant and confirmed in a multivariable Cox regression analysis.  Similar
results  were  found  in  several  smaller  studies.  Braun  et  al.  demonstrated  unfavorable
prognosis  with  regard  to  distant  DFS  in  BM  positive  patients  at  the  time  of  diagnosis
[7].  DTC presence  remained a  strong prognostic  factor  also  in  a  subset  of  64  optimally
debulked  patients  (p  =  0.002),  which  highlights  the  role  of  DTC detection  especially  in
patients who received successful surgical cytoreduction. We previously reported a signif‐
icant correlation of  positive BM status with reduced DFS in a group of  112 stage FIGO
I-III  ovarian  cancer  patients  [6].  Interestingly,  in  some  studies,  the  presence  of  isolated
tumor cells  in  secondary sites,  such as  BM and blood,  was  also  associated with  higher
risk for recurrence [10],  [6].  Therefore,  it  might be speculated that  hematogenous tumor
cell dissemination may serve as an indicator of a more aggressive phenotype of the pri‐
mary disease that  is  likely to cause local  relapse.  In contrast,  other authors reported no
significant correlation between DTC detection and clinical outcome in ovarian cancer [19,
28].  This  discrepancy might  be  due to  differences  in  study protocols,  e.g.  time point  of
BM sample  collection  (pre-  vs.  postoperative  aspiration).  Hypothetically,  a  transient  in‐
crease in cancer cell dissemination from the primary tumor due to intraoperative manip‐
ulation could contribute to false-positive results and therefore affect further analysis [29].
2.2. Circulating tumor cells
Bone marrow biopsy represents an invasive procedure not well tolerated by many patients.
Therefore, detection of circulating tumor cells (CTC) by simple blood drawing has increas‐
ingly become a focus of translational research. Prognostic significance of CTC in peripheral
blood has been evaluated in breast cancer both in primary and metastatic disease [33, 34].
Two commercially available kits are currently in use for CTC detection in blood of breast
cancer patients: antibody-based CellSearch and RT-PCR-based AdnaTest. Both assays were
modified and validated in ovarian cancer patients (Table 1). Recently published trial by Po‐
veda et al. based on a cohort of 216 patients with recurrent ovarian cancer, represents the
largest study so far on the impact of CTC presence on survival [10]. Using CellSearch test
increased CTC numbers (> 1 cell / 7.5 ml blood) were found in 14% of these patients before
the beginning of treatment. Detection of CTC in peripheral blood was associated with signif‐
icantly impaired prognosis. In the study by Aktas et al., including 86 ovarian cancer pa‐
tients, a modified AdnaTest kit was used to detect cells expressing EpCAM, MUC-1, HER-2
or CA 125-transcripts [8]. CTC positivity rate of 19% observed in this cohort was associated
with significantly shorter survival independent of the time of blood sampling (before sur‐
gery or after chemotherapy). Similar results were obtained by Fan et al. in a trial of 66 pri‐
mary ovarian cancer patients [32]. In contrast, Marth et al. reported a 12% positivity rate
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irrespective of tumor stage but observed no correlation with clinical outcome [19]. Interest‐
ingly, positive finding in the blood was highly associated with DTC detection in bone mar‐
row. Smaller studies showed varying CTC incidence, depending on methodology [35, 36].
Author N Method
Median
follow-up
[months]
Positivity rate Prognosticsignificance
Fehm [26] 414 DTC (ICC) 34 27% OS, DFS 1
Banys [6] 112 DTC (ICC) 12 25% DFS
Braun [7] 108 DTC (ICC) 45 30% DFS
Aktas [8] 95 DTC (ICC) 28 35% n.s.
Schindlbeck [9] 90 DTC (ICC) 28 23% DDFS
Marth [19] 73 DTC (immunobeads) 25 21% n.s.
Wimberger [30] 62 DTC (ICC) 18 54% DFS 2
Poveda [10] 216 CTC (ICC: CellSearch) 3 14% 4 PFS, OS
Sehouli [17] 167 CTC (ICC) 46 n.s.
Marth [19] 90 CTC (immunomagnetic beads) 25 12% n.s.
Aktas [8] 86 CTC (Multiplex-RT-PCR: AdnaTest) 28 19% OS 5
Heubner [31] 68 Circulating 20S-proteasomes 19 - OS
Fan [32] 66 CTC (immunofluorescence, cellinvasion assay) 18 61% DFS
Wimberger [30] 62 Circulating nucleosomes, DNA,protease and caspase activity 18 - DFS, OS
Abbreviations: DFS – disease-free survival, DDFS – distant disease-free survival, DTC – disseminated tumor cells in bone
marrow, ICC – immunocytochemistry, n.s. – not significant, PFS – progression-free survival
1 Determined by multivariate Cox regression analysis
2 DTC detected after chemotherapy
3 Relapsed ovarian cancer
4 Two or more CTC
5 Both before and after chemotherapy
Table 1. Prognostic relevance of disseminated and circulating tumor cells in ovarian cancer.
2.3. Therapy monitoring
Beyond the prognostic value of DTC/CTC detection, monitoring of minimal residual disease
(MRD) during and after treatment offers the opportunity to assess response to therapy and
evaluate the residual risk of recurrence. Changes in MRD represent the only clinical parame‐
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ter available after surgical removal of the primary tumor. While tumor markers are estab‐
lished tools for the evaluation of treatment efficacy in patients with advanced ovarian
cancer, CA 125 levels fall during adjuvant chemotherapy and remain often below cut-off
values after completion of first line systemic treatment even though significant number of
patients will suffer from relapse within five years. Furthermore, the clinical relevance of se‐
rial CA125 measurements for early detection and treatment of disease recurrence is current‐
ly being controversially discussed [37]. In this regard, the detection of isolated tumor cells in
bone marrow or peripheral blood might serve as a parameter for occult tumor load after
completion of first line therapy. DTC persistence despite adjuvant treatment is so far an in‐
dependent prognostic factor in patients with primary breast cancer [38]. Whether persistent
DTC influence prognosis in ovarian cancer patients, is currently being investigated. In the
study by Wimberger et al. DTC counts before and after the first line systemic treatment were
correlated to clinical course of disease in 30 ovarian cancer patients; 54% of these patients
presented with DTC after first-line chemotherapy. Marked increase in DTC counts was asso‐
ciated with shortened progression free survival [15].
Evaluation of treatment efficacy in ovarian cancer patients after optimal surgical cytoreduc‐
tion and completion of first line systemic therapy is based on clinical, radiological and bio‐
logical (tumor marker CA125) criteria. However, a reliable tool to assess long-term
prognosis has so far not been established. Therefore, a solid therapy monitoring tool could
help to identify a group of high-risk patients who potentially benefit from additional treat‐
ment. New studies are required to evaluate whether persistent DTC indeed predict a worse
prognosis and if these cells may be targeted by secondary adjuvant therapy.
3. Cancer stem cell model
An important hypothesis on tumor initiation and progression has attracted much attention
in the ovarian cancer research in the past decade. In contrast to stochastic model that postu‐
lates every cell as a potential source of malignant transformation, the cancer stem cell model,
a theory introduced over a century ago, proposes that tumors are organized in a cellular hi‐
erarchy, in which cancer stem cell (CSC) are the only cells with tumorigenic potential. Ac‐
cordingly, tumors are initiated in cancer stem cells or their immediate progeny through
imbalance of self-renewal and apoptosis; these tumors contain a cellular subpopulation that
retains key stem cell feature [39]. This small cell group with unlimited proliferative potential
is assumed to play a marked role in initiation and development of several tumor entities like
retinoblastoma, gastrointestinal cancer as well as breast and ovarian cancer [12]. The cancer
stem cell concept has important implications for understanding the process of carcinogene‐
sis as well as for designing new treatment strategies. Due to their long life, CSC are more
likely to acquire transforming mutations; further, they seem more resistant to apoptosis and
DNA damage and are therefore able to persist beyond therapy. New evidence in support of
the cancer stem cell model has arisen due to advances in stem cell biology and the introduc‐
tion of novel animal models to assess self-renewal and challenge the validity of this concept.
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The cancer stem cell hypothesis holds that CSC are responsible for phenomena like drug re‐
sistance, tumor dormancy or minimal residual disease and may persist beyond chemothera‐
py and repopulate the tumor leading to relapse [11]. The stem cell subpopulation, but not
the remaining differentiated cancer cells in the tumor, can sustain tumor formation and
growth due to their high tumor-initiating potential. So far, such cells have been found in
several solid tumors, such as colon [40], breast [41] and ovarian cancer [13, 42, 43]. Indeed, in
accordance with recent studies, ovarian cancer cell lines feature ´side population´ cells (SP)
with potential to differentiate into other morphological entities. Thus, this pluripotent sub‐
clone with stem cell-like features is considered a marker of CSC presence [14]. The detection
of CSC is based on the presence of extracellular markers assumed to be stem cell-specific;
commonly identified markers are CD44, CD133, and CD24, which are found in prostate,
breast, pancreas, and ovarian cancer. It remains under discussion whether these parameters
are universal markers relevant for CSC derived from all tumor types; for ovarian cancer,
multiple markers have been described for the stem cell-like tumor initiating cells.
Owing to aggressive natural course of disease and emergence of multidrug resistance, an es‐
sential role of cancer stem cells has been postulated in ovarian cancer [13, 44]. In the study
by Szotek et al. SP cells have been encountered in ovarian cancer cell lines as well as in pri‐
mary ascites cancer cells [13]. In the trial by Hosonuma et al. in 18 of 28 ovarian cancer pa‐
tients samples side population cells could be detected. SP cells occurred more often in
relapsed and metastatic patients and SP positivity predicted significantly reduced overall
survival [15]. A high proportion of CD44+ stem cells in ovarian cancer was reported to be an
independent predictor of poor progression-free survival [45].
As previously mentioned, CSC are considered responsible for high emergence of drug re‐
sistance in the natural history of ovarian cancer, since standard therapies fail to target pluri‐
potent tumor-initiating cells [13]. Latifi et al. could show in their recently published trial, the
ability of cisplatin chemotherapy to generate residual tumor cells with mesenchymal stem
cell-like characteristics in vitro [46]. Accordingly, new therapeutic strategies have to be de‐
veloped to target these cells by identifying their specific antigens. However, very few tumor
characteristics have been described to target the subset of CSC.
Based on an animal model, Bapat et al. reported the isolation and identification of ovarian
cancer stem cells [42]. In an in vitro model comprised of 19 spontaneously immortalized
clones derived from an advanced-stage patient, the authors demonstrated the ability of two
clones with stem cell-like characteristics to differentiate to grow as spheroids and form xen‐
ografts in an animal model (nude mice). These cells were shown to express CD44, E-cadher‐
in, and the stem cell factors Nestin, Nanong, and Oct-4.
3.1. DTC and cancer stem cell model
A currently discussed theory postulate DTC and CTC, the presumed precursor cells of sys‐
temic metastatic disease, to be in fact cancer stem cells. These observations have been so far
reported in breast cancer studies. Balic et al. analyzed bone marrow specimens from 50 pri‐
mary breast cancer patients; 33-100% of DTC of every patient exhibited stem cell-like pheno‐
type: CD44+ / CD24 low/- [47]. This prevalence is estimated for less than 10% in primary
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tumor suggesting much higher, stem cell like self-renewal and tumorigenic potential in
DTC. Aktas et al. detected stem cells markers on CTC in peripheral blood of metastatic
breast cancer patients [41]. Moreover, Abraham et al. reported that high proportion of stem
cell-like subpopulation in primary breast cancer correlate with a higher prevalence of dis‐
tant metastases [48]. As breast cancer stem cells have been shown to be generally triple-neg‐
ative, basal-like CTC, independent of the phenotype of the primary tumor, support the
cancer stem cell theory [20, 49, 50]. However, this aspect has not been researched in ovarian
cancer so far. Therefore, futher studies have to be performed to evaluate whether isolated
tumor cells in extraperitoneal sites, such as blood and bone marrow, may reflect ovarian
cancer stem cell population.
4. Conclusions
Despite advances in surgical and systemic therapy, ovarian cancer leads to relapse in 60% of
patients within 5 years, resulting in impaired clinical outcome. In the last decades, novel bio‐
markers have been introduced for better prediction and prognostication [51]. Early hema‐
togenous dissemination of single tumor cells is a general phenomenon observed in most
solid tumors of epithelial origin; recent data supports the clinical relevance of disseminated
and circulating tumor cells (DTC/CTC) in ovarian cancer. A currently discussed hypothesis
postulates isolated tumor cells in secondary sites to be not only the presumed precursors of
systemic metastatic disease but in fact pluripotent ‘cancer stem cells’. Future research will
clarify the implications of these findings for clinical management of ovarian cancer patients.
While the published data do not support the use of DTC/CTC detection for early detection
or screening purposes, its role as an important prognostic factor has been confirmed in sev‐
eral studies. One of the most promising applications of DTC detection is their use as a thera‐
py monitoring tool. DTC persistence beyond surgery and adjuvant chemotherapy may help
to identify patients at risk of developing a relapse.
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